Janssen registers Phase 2 trial of RIPTAC drug JNJ-101556143 in resistant prostate cancer
A new Phase 2 trial testing JNJ-101556143 in metastatic androgen pathway modulation-resistant prostate cancer is recruiting, according to a ClinicalTrials.gov record posted September 21, 2026.
This week's update covers a single newly posted trial record for Janssen's prostate cancer candidate.
- A Phase 2, open-label, multicenter, single-arm trial of JNJ-101556143, described as an androgen receptor-targeted RIPTAC therapeutic, is being studied in participants with metastatic androgen pathway modulation-resistant prostate cancer.1 The study is sponsored by Janssen Research & Development, LLC and its status is listed as recruiting, with an actual start date of September 16, 2026, and estimated primary completion of May 17, 2029. Enrollment is estimated at 100 participants, and the primary outcome is overall response rate, defined as confirmed complete or partial response per RECIST v1.1 criteria by blinded independent central review.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.